<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40731782</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>26</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1152</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina61071152</ELocationID><Abstract><AbstractText><i>Background and Objectives</i>: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly used in type 2 diabetes (T2D) due to their cardiorenal benefits and weight-lowering effects. However, concerns have emerged regarding their potential adverse impact on lean mass and muscle strength particularly in patients at risk for sarcopenia. This study aimed to evaluate the effects of empagliflozin on skeletal muscle mass. Secondary objectives were to assess changes in glycemic control, body weight, fat mass and handgrip strength. <i>Materials and Methods</i>: In this 24-week real-world observational study, 31 adult patients with T2D were assigned to either empagliflozin or non-SGLT2i treatment groups. Patients did not receive a high-protein diet, a resistance exercise program or any other weight-reducing medications such as glucagon-like peptide-1 (GLP-1)-based therapies. Anthropometric measurements, body composition via bioelectrical impedance analysis (BIA), and handgrip strength testing were performed at baseline and after 6 months. Sarcopenia was defined according to EWGSOP2 criteria. <i>Results</i>: The empagliflozin group showed significant improvements in HbA1c, fasting plasma glucose, body weight, waist circumference, and fat mass (<i>p</i> &lt; 0.05 for all). No significant changes were observed in the empagliflozin group after 6 months in appendicular skeletal muscle mass index (from 7.81 &#xb1; 1.33 kg/m<sup>2</sup> to 7.84 &#xb1; 1.38 kg/m<sup>2</sup>, <i>p</i> = 0.154). No statistically significant changes were observed in handgrip strength in either group. <i>Conclusions</i>: Empagliflozin treatment over six months led to favorable changes in metabolic parameters and fat mass without detrimental effects on skeletal muscle mass or muscle strength. In clinical practice, the selection of antidiabetic therapies should consider individual glycemic targets, cardiovascular and renal risks, weight management, comorbidities and sarcopenia risk. Resistance exercises and adequate dietary protein intake should be recommended to preserve muscle mass in at-risk patients. Larger randomized trials are needed to confirm the long-term effects of SGLT2 inhibitors on body composition particularly in older adults.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>&#xc7;etin</LastName><ForeName>Deniz</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9144-4018</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Faculty of Medicine, Ayd&#x131;n Adnan Menderes University, Ayd&#x131;n 09000, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilgili</LastName><ForeName>Elif</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Faculty of Medicine, Ayd&#x131;n Adnan Menderes University, Ayd&#x131;n 09000, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koma&#xe7;</LastName><ForeName>&#xd6;mer</ForeName><Initials>&#xd6;</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Faculty of Medicine, Ayd&#x131;n Adnan Menderes University, Ayd&#x131;n 09000, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeti&#x15f;ken</LastName><ForeName>Merve</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Faculty of Medicine, Ayd&#x131;n Adnan Menderes University, Ayd&#x131;n 09000, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;ney</LastName><ForeName>Engin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Faculty of Medicine, Ayd&#x131;n Adnan Menderes University, Ayd&#x131;n 09000, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>HDC1R2M35U</RegistryNumber><NameOfSubstance UI="C570240">empagliflozin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005960">Glucosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001559" MajorTopicYN="Y">Benzhydryl Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055948" MajorTopicYN="Y">Sarcopenia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001823" MajorTopicYN="Y">Body Composition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005960" MajorTopicYN="Y">Glucosides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="N">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053580" MajorTopicYN="Y">Muscle Strength</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018737" MajorTopicYN="N">Hand Strength</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SGLT2 inhibitors</Keyword><Keyword MajorTopicYN="N">body composition</Keyword><Keyword MajorTopicYN="N">empagliflozin</Keyword><Keyword MajorTopicYN="N">muscle strength</Keyword><Keyword MajorTopicYN="N">sarcopenia</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>30</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40731782</ArticleId><ArticleId IdType="pmc">PMC12299443</ArticleId><ArticleId IdType="doi">10.3390/medicina61071152</ArticleId><ArticleId IdType="pii">medicina61071152</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>International Diabetes Federation  . IDF Diabetes Atlas. 11th ed. The International Diabetes Federation; Brussels, Belgium: 2025.  [(accessed on 7 April 2025)].  Available online:  https://diabetesatlas.org.</Citation></Reference><Reference><Citation>Satman I., Omer B., Tutuncu Y., Kalaca S., Gedik S., Dinccag N., Karsidag K., Genc S., Telci A., Canbaz B., et al. Twelve-Year Trends in the Prevalence and Risk Factors of Diabetes and Prediabetes in Turkish Adults. Eur. J. Epidemiol. 2013;28:169&#x2013;180. doi: 10.1007/s10654-013-9771-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-013-9771-5</ArticleId><ArticleId IdType="pmc">PMC3604592</ArticleId><ArticleId IdType="pubmed">23407904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonmez A., Haymana C., Bayram F., Salman S., Dizdar O.S., Gurkan E., Kargili Carl&#x131;oglu A., Barcin C., Sabuncu T., Satman I., et al. Turkish Nationwide Survey of Glycemic and Other Metabolic Parameters of Patients with Diabetes Mellitus (TEMD study) Diabetes Res. Clin. Pract. 2018;146:138&#x2013;147. doi: 10.1016/j.diabres.2018.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2018.09.010</ArticleId><ArticleId IdType="pubmed">30244051</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Zhao Y., Chen S., Shao H. Anti-diabetic drugs and sarcopenia: Emerging links, mechanistic insights, and clinical implications. J. Cachexia Sarcopenia Muscle. 2021;12:1368&#x2013;1379. doi: 10.1002/jcsm.12838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.12838</ArticleId><ArticleId IdType="pmc">PMC8718027</ArticleId><ArticleId IdType="pubmed">34676695</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippin L.I., Teixeira V.N., da Silva M.P., Miraglia F., da Silva F.S. Sarcopenia: A Predictor of Mortality and the Need for Early Diagnosis and Intervention. Aging Clin. Exp. Res. 2015;27:249&#x2013;254. doi: 10.1007/s40520-014-0281-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40520-014-0281-4</ArticleId><ArticleId IdType="pubmed">25365952</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Larsson S.C. Epidemiology of Sarcopenia: Prevalence, Risk Factors, and Consequences. Metabolism. 2023;144:155533. doi: 10.1016/j.metabol.2023.155533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2023.155533</ArticleId><ArticleId IdType="pubmed">36907247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali S., Garcia J.M. Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options&#x2014;A Mini-Review. Gerontology. 2014;60:294&#x2013;305. doi: 10.1159/000356760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000356760</ArticleId><ArticleId IdType="pmc">PMC4112511</ArticleId><ArticleId IdType="pubmed">24731978</ArticleId></ArticleIdList></Reference><Reference><Citation>Salom Vendrell C., Garc&#xed;a Tercero E., Moro Hern&#xe1;ndez J.B., Cedeno-Veloz B.A. Sarcopenia as a Little-Recognized Comorbidity of Type II Diabetes Mellitus: A Review of the Diagnosis and Treatment. Nutrients. 2023;15:4149. doi: 10.3390/nu15194149.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15194149</ArticleId><ArticleId IdType="pmc">PMC10574035</ArticleId><ArticleId IdType="pubmed">37836433</ArticleId></ArticleIdList></Reference><Reference><Citation>Damluji A.A., Alfaraidhy M., AlHajri N., Rohant N.N., Kumar M., Al Malouf C., Bahrainy S., Ji Kwak M., Batchelor W.B., Forman D.E., et al. Sarcopenia and Cardiovascular Diseases. Circulation. 2023;147:1534&#x2013;1553. doi: 10.1161/CIRCULATIONAHA.123.064071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.123.064071</ArticleId><ArticleId IdType="pmc">PMC10180053</ArticleId><ArticleId IdType="pubmed">37186680</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzo A., Massimino E., Riccardi G., Della Pepa G. A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors. Nutrients. 2021;13:183. doi: 10.3390/nu13010183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13010183</ArticleId><ArticleId IdType="pmc">PMC7826709</ArticleId><ArticleId IdType="pubmed">33435310</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care. 2024;47:158&#x2013;178. doi: 10.2337/dc24-S009.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc24-S009</ArticleId><ArticleId IdType="pmc">PMC10725810</ArticleId><ArticleId IdType="pubmed">38078590</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Liu Y., Lin T., Hou L., Song Q., Ge N., Yue J. Reliability and Validity of Two Hand Dynamometers When Used by Community-Dwelling Adults Aged over 50 Years. BMC Geriatr. 2022;22:580. doi: 10.1186/s12877-022-03270-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-022-03270-6</ArticleId><ArticleId IdType="pmc">PMC9284760</ArticleId><ArticleId IdType="pubmed">35840905</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruy&#xe8;re O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., et al. Sarcopenia: Revised European Consensus on Definition and Diagnosis. Age Ageing. 2019;48:16&#x2013;31. doi: 10.1093/ageing/afy169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afy169</ArticleId><ArticleId IdType="pmc">PMC6322506</ArticleId><ArticleId IdType="pubmed">30312372</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrannini E., Muscelli E., Frascerra S., Baldi S., Mari A., Heise T., Broedl U.C., Woerle H.J. Metabolic Response to Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetic Patients. J. Clin. Investig. 2014;124:499&#x2013;508. doi: 10.1172/JCI72227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI72227</ArticleId><ArticleId IdType="pmc">PMC3904627</ArticleId><ArticleId IdType="pubmed">24463454</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergi G., De Rui M., Stubbs B., Veronese N., Manzato E. Measurement of Lean Body Mass Using Bioelectrical Impedance Analysis: A Consideration of the Pros and Cons. Aging Clin. Exp. Res. 2017;29:591&#x2013;597. doi: 10.1007/s40520-016-0622-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40520-016-0622-6</ArticleId><ArticleId IdType="pubmed">27568020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.M., Jang H.C., Lim S. Differences Among Skeletal Muscle Mass Indices Derived from Height-, Weight-, and Body Mass Index-Adjusted Models in Assessing Sarcopenia. Korean J. Intern. Med. 2016;31:643&#x2013;650. doi: 10.3904/kjim.2016.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2016.015</ArticleId><ArticleId IdType="pmc">PMC4939509</ArticleId><ArticleId IdType="pubmed">27334763</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki T. Sarcopenia, Frailty Circle and Treatment with Sodium-Glucose Cotransporter 2 Inhibitors. J. Diabetes Investig. 2019;10:193&#x2013;195. doi: 10.1111/jdi.12966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.12966</ArticleId><ArticleId IdType="pmc">PMC6400153</ArticleId><ArticleId IdType="pubmed">30369086</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsurutani Y., Nakai K., Inoue K., Azuma K., Mukai S., Maruyama S., Iizuka T., Matsuzawa Y., Saito J., Omura M., et al. Comparative Study of the Effects of Ipragliflozin and Sitagliptin on Multiple Metabolic Variables in Japanese Patients with Type 2 Diabetes: A Multicentre, Randomized, Prospective, Open-Label, Active-Controlled Study. Diabetes Obes. Metab. 2018;20:2675&#x2013;2679. doi: 10.1111/dom.13421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13421</ArticleId><ArticleId IdType="pubmed">29893003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiyama S., Jinnouchi H., Kurinami N., Hieshima K., Yoshida A., Jinnouchi K., Nishimura H., Suzuki T., Miyamoto F., Kajiwara K., et al. Dapagliflozin Reduces Fat Mass Without Affecting Muscle Mass in Type 2 Diabetes. J. Atheroscler. Thromb. 2018;25:467&#x2013;476. doi: 10.5551/jat.40873.</Citation><ArticleIdList><ArticleId IdType="doi">10.5551/jat.40873</ArticleId><ArticleId IdType="pmc">PMC6005223</ArticleId><ArticleId IdType="pubmed">29225209</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Y.H., Liu S.C., Lee C.C., Sun F.J., Liu J.J. Effect of Empagliflozin Versus Linagliptin on Body Composition in Asian Patients with Type 2 Diabetes Treated with Premixed Insulin. Sci. Rep. 2022;12:17065. doi: 10.1038/s41598-022-21486-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-21486-9</ArticleId><ArticleId IdType="pmc">PMC9556548</ArticleId><ArticleId IdType="pubmed">36224294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Qi Z., Wang Y., Song D., Zhu D. Effect of Sodium-Glucose Transporter 2 Inhibitors on Sarcopenia in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Front. Endocrinol. 2023;14:1203666. doi: 10.3389/fendo.2023.1203666.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1203666</ArticleId><ArticleId IdType="pmc">PMC10351980</ArticleId><ArticleId IdType="pubmed">37465122</ArticleId></ArticleIdList></Reference><Reference><Citation>Morciano C., Gugliandolo S., Capece U., Di Giuseppe G., Mezza T., Ciccarelli G., Soldovieri L., Brunetti M., Avolio A., Splendore A., et al. SGLT2 inhibition and adipose tissue metabolism: Current outlook and perspectives. Cardiovasc. Diabetol. 2024;23:449. doi: 10.1186/s12933-024-02539-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-024-02539-x</ArticleId><ArticleId IdType="pmc">PMC11660748</ArticleId><ArticleId IdType="pubmed">39702365</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Ota T. Emerging Roles of SGLT2 Inhibitors in Obesity and Insulin Resistance: Focus on Fat Browning and Macrophage Polarization. Adipocyte. 2018;7:121&#x2013;128. doi: 10.1080/21623945.2017.1413516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21623945.2017.1413516</ArticleId><ArticleId IdType="pmc">PMC6152529</ArticleId><ArticleId IdType="pubmed">29376471</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaheer A., Kumar A., Menon P., Jallo M., Basha S. Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus. J. Clin. Med. Res. 2021;13:355&#x2013;362. doi: 10.14740/jocmr4510.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jocmr4510</ArticleId><ArticleId IdType="pmc">PMC8256907</ArticleId><ArticleId IdType="pubmed">34267843</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai S., Jojima T., Iijima T., Tomaru T., Usui I., Aso Y. Empagliflozin Decreases the Plasma Concentration of Plasminogen Activator Inhibitor-1 (PAI-1) in Patients with Type 2 Diabetes: Association with Improvement of Fibrinolysis. J. Diabetes Complicat. 2020;34:107703. doi: 10.1016/j.jdiacomp.2020.107703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2020.107703</ArticleId><ArticleId IdType="pubmed">32883567</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaap L.A., van Schoor N.M., Lips P., Visser M. Associations of Sarcopenia Definitions, and Their Components, With the Incidence of Recurrent Falling and Fractures: The Longitudinal Aging Study Amsterdam. J. Gerontol. A Biol. Sci. Med. Sci. 2018;73:1199&#x2013;1204. doi: 10.1093/gerona/glx245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glx245</ArticleId><ArticleId IdType="pubmed">29300839</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M., Meguro S., Kawai T., Suzuki Y. Increased Grip Strength with Sodium-Glucose Cotransporter 2. J. Diabetes. 2016;8:736&#x2013;737. doi: 10.1111/1753-0407.12402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1753-0407.12402</ArticleId><ArticleId IdType="pubmed">27038414</ArticleId></ArticleIdList></Reference><Reference><Citation>Drucker D.J. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care. 2024;47:1873&#x2013;1888. doi: 10.2337/dci24-0003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dci24-0003</ArticleId><ArticleId IdType="pubmed">38843460</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrimmon R.J., Catarig A.M., Frias J.P., Lausvig N.L., le Roux C.W., Thielke D., Lingvay I. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: A substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63:473&#x2013;485. doi: 10.1007/s00125-019-05065-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-019-05065-8</ArticleId><ArticleId IdType="pmc">PMC6997246</ArticleId><ArticleId IdType="pubmed">31897524</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantanetti P., Cangelosi G., Alberti S., Di Marco S., Michetti G., Cerasoli G., Di Giacinti M., Coacci S., Francucci N., Petrelli F., et al. Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice. Front. Endocrinol. 2024;15:1394506. doi: 10.3389/fendo.2024.1394506.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2024.1394506</ArticleId><ArticleId IdType="pmc">PMC11250060</ArticleId><ArticleId IdType="pubmed">39015186</ArticleId></ArticleIdList></Reference><Reference><Citation>Look M., Dunn J.P., Kushner R.F., Cao D., Harris C., Gibble T.H., Stefanski A., Griffin R. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes. Metab. 2025;27:2720&#x2013;2729. doi: 10.1111/dom.16275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.16275</ArticleId><ArticleId IdType="pmc">PMC11965027</ArticleId><ArticleId IdType="pubmed">39996356</ArticleId></ArticleIdList></Reference><Reference><Citation>Neeland I.J., Linge J., Birkenfeld A.L. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes. Metab. 2024;26:16&#x2013;27. doi: 10.1111/dom.15728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.15728</ArticleId><ArticleId IdType="pubmed">38937282</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y., Shi Q., Nong K., Li S., Yue J., Huang J., Dong B., Beauchamp M., Hao Q. Exercise for sarcopenia in older people: A systematic review and network meta-analysis. J. Cachexia Sarcopenia Muscle. 2023;14:1199&#x2013;1211. doi: 10.1002/jcsm.13225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.13225</ArticleId><ArticleId IdType="pmc">PMC10235889</ArticleId><ArticleId IdType="pubmed">37057640</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalit A., Gerontiti E., Boutzios G., Korakianiti E., Kanouta F., Vasileiou V., Psaltopoulou T., Paschou S.A. Nutrition of aging people with diabetes mellitus: Focus on sarcopenia. Maturitas. 2024;185:107975. doi: 10.1016/j.maturitas.2024.107975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.maturitas.2024.107975</ArticleId><ArticleId IdType="pubmed">38522145</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>